Business Summary
Tivic Health Systems, Inc. (Nasdaq: TIVC) is a late-stage biopharmaceutical company headquartered in San Antonio, Texas that underwent a fundamental strategic transformation during fiscal year 2025. The company pivoted from a diversified bioelectronic medical device company into a focused biopharmaceutical company built around its TLR5 agonist franchise. In February 2025, Tivic acquired worldwide exclusive license rights to Entolimod — a recombinant TLR5 agonist with 15+ years of development history, over 40 animal and human trials, and $140 million of prior investment including $35.6 million from U.S. government agencies (DoD/DTRA, NASA, NIH). The company exited its ClearUP consumer sinus device business in December 2025 and suspended its cervical vagus nerve stimulation platform to concentrate all resources on the TLR5 program. In December 2025, Tivic established Velocity Bioworks, Inc. (VBI) — a wholly owned CDMO subsidiary — through acquisition of manufacturing assets from Scorpius Holdings, Inc., supported by a...
AI-generated summary of Item 1 (Business) from the 10-K filed Mar 30, 2026 — View filing on SEC.gov. May contain errors — refer to the filing for authoritative information.
Across SEC filings
Insider trades · Form 4
Latest filings
- Dean Zikria 2026-09-24 Award
- Lisa G Wolf 2026-09-24 Exercise
- Lisa G Wolf 2026-06-18 Exercise
- Michael K Handley 2026-05-20 Exercise
- Melinda Lackey 2026-05-04 Award
Federal lobbying · LD-2
Annual results · 10-K
Fiscal 20255%+ holders · 13D/G
2 filers| Filer | % of class | Filed |
|---|---|---|
| 3i LP 13G VBIO | 9.9% | 2026-11-12 |
| 3i LP 13D VBIO | 9.9% | 2026-08-20 |
| Murchinson Ltd 13G VBIO | 10.0% | 2026-07-17 |
Latest Schedule 13D or 13G from each filer; stakes a filer has reported closed are left out.